Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

Hepatology

Volumn 34, Issue 1, 2001, Pages 139-145

  Yuen, Man Fung ^a   Hui, Chee Kin ^a   Cheng, Chi Chung ^a   Wu, Chi Hang ^a   Lai, Yim Ping ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CARRIER; DRUG EFFECT; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME;

EID: 0034962643     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.25273     Document Type: Article

References (47)

1. Hepatitis B. Global importance of and need for control
2. Chronic hepatitis B in Hong Kong: Immunisation strategies for the control of hepatitis B virus infection
3. Control of hepatitis B by immunization: Global perspective
4. Chronic type B hepatitis and the "healthy" HBsAg carrier state
5. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg
6. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy
7. Detection of hepatitis B virus DNA in serum by polymerase chain reaction
8. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B
9. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen
10. Randomized controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection
11. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
12. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
13. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy
14. Treatment of chronic hepatitis B with interferon: Experience in western countries
15. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
16. Treatment of chronic hepatitis B with interferon: Experience in Asian patients
17. Transmission of HBsAg from mother to infant in four ethnic groups
18. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
19. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
20. Cost-effectiveness of interferon-2b treatment for hepatitis B antigen-positive chronic hepatitis B
21. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa
22. Long-term remission of chronic hepatitis B after alphainterferon therapy
23. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: Implications for interferon therapy
24. Natural history of chronic hepatitis B virus infection: New light on an old story
25. Hepatocellular carcinoma in Chinese males and females
26. Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong
27. Hepatitis B virus infection, its sequelae, and prevention in Taiwan
28. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma
29. Maternal transmission of hepatitis B surface antigen in patients with hepatocellular carcinoma in Taiwan
30. Natural history of chronic hepatitis B in the Chinese: Prognostic significance of HBeAg/anti-HBe positivity
31. Monitoring disease progression and the effect of treatment in chronic hepatitis B
32. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
33. Effect of interferon on hepatitis B
34. Do Asian HBV carriers differ from non-Asian carriers?
35. Placebo-controlled trial of recombinant 2-interferon in Chinese HBsAg-carrier children
36. Effect of recombinant alpha-2 interferon with or without prednisone in Chinese HBsAg carrier children
37. Long-term follow up in a randomized controlled trial of recombinant alpha-2 interferon in Chinese patients with chronic hepatitis B infection
38. Re-evaluation of alpha-interferon treatment of chronic hepatitis B using polymerase chain reaction
39. Chronic hepatitis
40. Treatment of chronic hepatitis B with interferon: Experience in western countries
41. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
42. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
43. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy of lymphoma patients
44. A case of HBsAg positive liver cirrhosis who died after withdrawal of steroid
45. Two fatal cases of hepatitis B virus carriers after corticosteroid therapy for bronchial asthma
46. A one-year trial of lamivudine for chronic hepatitis B